Form 4: Alnylam Pharmaceuticals Executive Exercises and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 27, 2025, Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, exercised options to acquire 48,876 shares of common stock at a price of $88.95 per share.
- He then sold 52,592 shares of common stock at $285 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on September 11, 2024.
- Following these transactions, Garg directly owns 11,989 shares of Alnylam common stock.
- He also indirectly owns 431 shares through a managed account and 250 shares through a trust where his spouse is a co-trustee.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment.
Positives
- The transactions were pre-planned under a Rule 10b5-1(c) trading plan, suggesting they were not based on insider information at the time of the trades.
Future Outlook
The document does not contain any specific forward-looking statements.
Industry Context
Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry where insider knowledge of clinical trial results or regulatory decisions can significantly impact stock prices. Rule 10b5-1 plans are used to mitigate concerns about insider trading.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include stock options to align management's interests with those of shareholders.
- The use of Rule 10b5-1 trading plans is a standard practice among executives to avoid accusations of insider trading.
- The size of the transaction is not unusual for an executive at Garg's level in a company of Alnylam's size.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of adoption of Rule 10b5-1(c) trading plan |
| 01/27/2025 | Date of stock option exercise and share sale |
| 01/29/2025 | Date of Form 4 filing |
| 12/18/2025 | Expiration date of the stock options exercised |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.